PMID- 25422248
OWN - NLM
STAT- MEDLINE
DCOM- 20150730
LR  - 20190606
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 15
IP  - 21
DP  - 2014
TI  - Serum cathepsin B to cystatin C ratio as a potential marker for the diagnosis of 
      cholangiocarcinoma.
PG  - 9511-5
AB  - Cholangiocarcinoma (CCA) is a cancer of the bile duct epithelial cells. The 
      highest incidence rate of CCA with a poor prognosis and poor response to 
      chemotherapy is found in Southeast Asian countries, especially in northeastern 
      Thailand and Lao PDR. Cathepsin B is a lysosomal cysteine protease which is 
      regulated by cysteine proteinase inhibitors such as cystatin C. Elevation of 
      cathepsin B levels in biological fluid has been observed in patients with 
      inflammatory diseases and many cancers. We aimed to investigate the serum 
      cathepsin B and cystatin C levels of CCA patients to evaluate the feasibility of 
      using cathepsin B and cystatin C as markers for the diagnosis of CCA. Fifty-six 
      sera from CCA patients, 17 with benign biliary diseases (BBD) and 13 from 
      controls were collected and the cathepsin B and cystatin C levels were 
      determined. In addition, cathepsin B expression was investigated 
      immunohistochemically for 9 matched-pairs of cancerous and adjacent tissues of 
      CCA patients. Serum cathepsin B, but not cystatin C, was significantly higher in 
      CCA and BBD patient groups compared to that in the control group. Consistently, 
      all cancerous tissues strongly expressed cathepsin B while adjacent tissues were 
      negative in 7 out of 9 cases. In contrast, serum cystatin C levels were 
      comparable between CCA and control groups, although serum cystatin C levels in 
      the BBD group was higher than that in the control or CCA groups. When the serum 
      cathepsin B to cystatin C ratio was calculated, that of the CCA group was 
      significantly higher than that of the control group, and, although statistically 
      not significant, the ratio of CCA group showed a trend to be higher than that of 
      the BBD group. Thus, the cathepsin B to cystatin C ratio might be used as an 
      alternative marker for aiding diagnosis of CCA.
FAU - Monsouvanh, Ammala
AU  - Monsouvanh A
AD  - Centre for Research and Development of Medical Diagnostic Laboratories, Faculty 
      of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand E-mail 
      : sirpat@kku.ac.th.
FAU - Proungvitaya, Tanakorn
AU  - Proungvitaya T
FAU - Limpaiboon, Temduang
AU  - Limpaiboon T
FAU - Wongkham, Chaisiri
AU  - Wongkham C
FAU - Wongkham, Sopit
AU  - Wongkham S
FAU - Luvira, Vor
AU  - Luvira V
FAU - Proungvitaya, Siriporn
AU  - Proungvitaya S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cystatin C)
RN  - EC 3.4.22.1 (Cathepsin B)
SB  - IM
MH  - Bile Duct Neoplasms/*blood/*diagnosis
MH  - Bile Ducts, Intrahepatic/metabolism
MH  - Biomarkers, Tumor/*blood
MH  - Case-Control Studies
MH  - Cathepsin B/*blood
MH  - Cholangiocarcinoma/*blood/*diagnosis
MH  - Cystatin C/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2014/11/26 06:00
MHDA- 2015/08/01 06:00
CRDT- 2014/11/26 06:00
PHST- 2014/11/26 06:00 [entrez]
PHST- 2014/11/26 06:00 [pubmed]
PHST- 2015/08/01 06:00 [medline]
AID - 10.7314/apjcp.2014.15.21.9511 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2014;15(21):9511-5. doi: 10.7314/apjcp.2014.15.21.9511.